This is further supported by a recent report showing that IL-17 antagonism lowers ACE2 (Pavel et al., 2021) (a receptor critically involved in SARS-CoV-2 cell entry) expression in psoriasis patients (Krueger et al., 2019), and that higher Th17 response has been associated with worse allergic asthma severity (Shi et al., 2011). This evidence concerns the gene IL17A and psoriasis.